Clinical Trials Browser

Interventional × Triple Negative Breast Neoplasms × pertuzumab × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

Phase 2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05020860 2025-02-27

RESPONSE

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms